Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2025-08-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Appendix 4E 3 pages 312.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4E – PRELIMINARY FINANCIAL REPORT' and is dated 28 August 2025. It covers the financial results for the year ended 30 June 2025, including income, loss, net tangible assets, control changes over entities, associates and joint ventures, and audit information. The document contains substantive financial data and analysis for a full fiscal year, indicating it is a comprehensive financial report. The Appendix 4E is a known Australian Securities Exchange (ASX) preliminary final report format, which is a type of annual report but preliminary. The document is 4348 characters long, which is relatively short but contains actual financial data, not just an announcement or a certification. It is not a mere announcement of report publication, nor a certification letter. Therefore, it should be classified as an Interim / Quarterly Report (IR) or Annual Report (10-K). Since it is a preliminary financial report for the full year ended 30 June 2025, it aligns more closely with an Annual Report (10-K) equivalent. However, Appendix 4E is specifically a preliminary report, often considered an interim report before the full annual report is published. Given the Australian context and the preliminary nature, the best fit is Interim / Quarterly Report (IR). FY 2025
2025-08-27 English
2025 Annual Report to Shareholders 94 pages 3.2MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT 2025' and contains detailed sections typical of an annual report, including a corporate directory, directors' information, auditor details, stock exchange listing, chairman's and CEO's letters to shareholders, operational and financial review, directors' report, financial statements, auditor's independence declaration, and ASX additional information. The content includes comprehensive financial and operational data, forward-looking statements, and detailed discussion of company activities and strategy. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification document. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2025-08-27 English
Appendix 4G 12 pages 382.6KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a completed Appendix 4G form lodged with ASX alongside the annual report, serving as a key to where governance disclosures can be found and confirming compliance with corporate governance recommendations. The document explicitly states it is not a substitute for the corporate governance statement or the annual report but a verification and key document. It contains no financial statements or substantive financial data but focuses on governance disclosures and compliance with ASX corporate governance principles. This matches the description of a Governance Information filing (CGR) rather than an Annual Report or Regulatory Filing. The document length (15,000 characters) and detailed governance content support this classification with high confidence.
2025-08-27 English
2025 Corporate Governance Statement 25 pages 522.1KB
Governance Information Classification · 95% confidence The document is titled 'Corporate Governance Statement – 30th June 2025' and discusses the company's corporate governance practices, board composition, diversity policy, and compliance with ASX Corporate Governance Council Principles and Recommendations. It includes detailed information about the board's responsibilities, structure, and policies but does not contain financial statements or financial performance data. The content focuses on governance practices rather than financial results or management discussion of financials. Therefore, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-27 English
Approval to Escalate Dosing in Kidney Disease Clinical Trial 4 pages 315.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 8 August 2025 from PYC Therapeutics Limited regarding progress in a clinical trial for a drug candidate PYC-003 targeting Polycystic Kidney Disease. It details the approval to escalate dosing in the trial and commencement of dosing in patients, describing clinical trial phases and next steps. The document is a corporate announcement about clinical trial progress and does not contain financial statements, earnings data, regulatory certifications, or detailed financial analysis. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not related to governance, capital changes, or legal proceedings. The document is a regulatory announcement informing shareholders and the market about clinical trial milestones and company progress. Given the content and nature, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories. The document length (5890 characters) and detailed content confirm it is not a brief report publication announcement but a substantive announcement. Confidence is high due to clear clinical trial update nature and absence of financial or governance report elements.
2025-08-07 English
Q3 2025 Investor Webinar Presentation 25 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from PYC Therapeutics Limited dated August 2025. It includes an introduction to the company, pipeline highlights, clinical-stage assets, disease focus, market size, and scientific rationale for their drug candidates. The content is structured as a presentation with slides, agenda, and detailed scientific and business information aimed at investors or stakeholders. There is no indication that this is a full annual or quarterly report, audit report, or regulatory filing. It is not a transcript of a call, nor a voting result or legal proceeding. The document is clearly a detailed investor presentation focusing on financials, strategy, and market position. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-07-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.